Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Revolutionary New Cancer Targeting Technology Described in Nature Medicine

Published: Monday, May 07, 2012
Last Updated: Monday, May 07, 2012
Bookmark and Share
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.

A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal, Nature Medicine.

The new reagents known as ImmTACs (Immune Mobilizing mTCR against Cancer) mobilize T cells to kill cancer cells and overcome immune tolerance to cancer.

The most advanced of Immunocore’s ImmTACs, a drug called IMCgp100, is already in clinical trials in the UK and US for the treatment of melanoma.

A second oncology ImmTAC, IMCmage1, is set to enter the clinic in both countries later this year and is applicable to the treatment of a large number of poorly served cancer indications.

Antibody-based drugs have become a mainstay of cancer treatment, but their use is limited to the small fraction of cancer targets that present as whole proteins on the cell surface. Most cancer targets are hidden inside cancerous cells where antibodies cannot reach them.

By contrast, T cells employ T Cell Receptors (TCRs) which target the peptide antigens found on the cell surface as a marker of cancer and viral infection inside the cell.

TCRs can potentially target any of the markers that are hallmarks of cancer and enables the development of drugs against cancers for which no antibody targets are known.

Unfortunately, the TCRs found naturally on the surface of killer T cells are primarily designed to recognize virally infected cells, and are often not sensitive enough to recognize cancer, which is then ignored by the immune system.

The scientists at Immunocore have managed to overcome this cancer recognition problem by boosting the ability of cancer-specific TCRs to bind to their targets with several million fold higher affinity than natural TCRs.

The company has subsequently equipped these engineered TCRs with the ability to activate all the T cells of the body to kill cancer, even those that would normally not recognize cancer, thereby bringing the entire weight of the immune system to bear against the disease.

Immunocore calls this new class of therapeutics ImmTACs (Immune Mobilizing mTCR Against Cancer). Dr Bent Jakobsen, Immunocore’s chief scientific officer, said: “The main hindrance to better cancer treatments is finding ways of targeting malignant cells without harming the body’s normal cells too much. This is where TCRs are uniquely compelling: for TCRs, there are potentially more targets available than for all other types of cancer treatments combined.

“However, for decades it has been thought that there was too little of each target on each cancer cell for it to be possible to make a reagent with which to find them. It’s a great pleasure, after fifteen years of research by a dedicated team of scientists, to be able to say that we have finally solved this problem.”

James Noble, Immunocore’s CEO, said: “The power of this new technology lies in its ability to be used for a host of cancers that are currently very difficult to treat. We look forward to building on the emerging clinical data and generating a robust pipeline of products over the coming years.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunocore and MedImmune Win the SCRIP Award
Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets.
Thursday, December 11, 2014
Immunocore and Lilly Enter Immunotherapy Agreement
Agreement to co-discover and co-develop novel cancer therapies.
Thursday, July 17, 2014
Immunocore Announces Re-organization of its Executive Management to Support Business Growth
Re-organization to support the continuing growth of Immunocore and Adaptimmune.
Thursday, March 27, 2014
Immunocore and MedImmune Enter Immunotherapy Agreement
Companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
Wednesday, January 08, 2014
Immunocore Appoints New Chairman of the Board
Dr Jonathan Knowles appointed as Company’s new executive Chairman of the Board of Directors.
Monday, November 18, 2013
Immunocore Appoints Chairman
Immunocore Limited announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 14, 2013
Immunocore Achieves Research Milestone in GSK Collaboration
Under the agreement announced in July, Immunocore will receive up to £142 million in pre-clinical milestone payments across the targets.
Thursday, November 07, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
IMCgp100 for has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed.
Monday, November 04, 2013
Immunocore Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma
Phase IIa study to optimize the dosing regimen and maximize the efficacy of IMCgp100.
Thursday, October 31, 2013
Immunocore Named One of Fierce 15 Leading Biotechs of 2013
Immunocore ranked among the top private biotech firms globally.
Thursday, September 26, 2013
Immunocore and Genentech Enter Strategic Alliance
Licensing agreement to develop ImmTACs for multiple cancer targets.
Thursday, June 27, 2013
Scientific News
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
The Genetics of Blood Pressure
Researchers have identifed areas of the genome associated with blood-pressure including 17 previously unknown loci.
Mosquito Genetics Determine Tastes
Study reveals mosuito's preference for human versus animal biting is determined by genetics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!